| [1] |
马丹丹，刘坤. 2018年全球癌症统计：乳腺癌发病和死亡人数统计[J/CD]. 中华乳腺病杂志(电子版), 2018, 12(6): 375.
|
| [2] |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10 125): 1023-1075.
|
| [3] |
Fisher B, Ravdin RG, Ausman RK, et al. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation[J]. Ann Surg, 1968, 168(3): 337-356.
|
| [4] |
Bonadonna G, Moliterni A, Zambetti M, et al. 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study[J]. BMJ, 2005, 330(7485): 217.
|
| [5] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials[J]. Lancet, 2012, 379(9814): 432-444.
|
| [6] |
Lyman GH, Yau L, Nakov R, et al. Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support[J]. Ann Oncol, 2018, 29(9): 1903-1910.
|
| [7] |
Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials[J]. J Clin Oncol, 2011, 29(24): 3214-3223.
|
| [8] |
Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance[J]. Semin Oncol, 1987, 14(4 Suppl 4): 29-33.
|
| [9] |
Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens[J]. Nat Clin Pract Oncol, 2006, 3(8): 406-407.
|
| [10] |
Norton L. Evolving concepts in the systemic drug therapy of breast cancer[J]. Semin Oncol, 1997, 24(4 Suppl 10)：S10-3-S10-10.
|
| [11] |
Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial c9741/cancer and leukemia group B trial 9741[J]. J Clin Oncol, 2003, 21(8): 1431-1439.
|
| [12] |
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology - breast cancer (version 1. 2022) [EB/OL].
URL
|
| [13] |
Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer[J]. N Engl J Med, 2008, 358(16): 1663-1671.
|
| [14] |
Sparano JA, Zhao F, Martino S, et al. Long-term follow-up of the E1199 phase Ⅲ trial evaluating the role of taxane and schedule in operable breast cancer[J]. J Clin Oncol, 2015, 33(21): 2353-2360.
|
| [15] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南(2021版) [M]. 北京：人民卫生出版社，2021.
|
| [16] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials[J]. Lancet, 2019, 393(10 179): 1440-1452.
|
| [17] |
Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer[J]. Oncology (Williston Park), 2008, 22(6): 614-623.
|
| [18] |
Sledge GW, Neuberg D, Bernardo P, et al. Phase Ⅲ trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)[J]. J Clin Oncol, 2003, 21(4): 588-592.
|
| [19] |
Dear RF, McGeechan K, Jenkins MC, et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer[J]. Cochrane Database Syst Rev, 2013, 2013(12): CD008792.
|
| [20] |
胡夕春，张剑，陈德滇，等. 中国蒽环类药物治疗乳腺癌专家共识[J]. 中国肿瘤临床，2018, 45(3): 120-125.
|
| [21] |
Ghersi D, Willson ML, Chan MM, et al. Taxane-containing regimens for metastatic breast cancer[J]. Cochrane Database Syst Rev, 2015, 2015(6)：CD003366.
|
| [22] |
Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial[J]. Ann Oncol, 2018, 29(8): 1763-1770.
|
| [23] |
Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 436-446.
|
| [24] |
Liu MC, Hillman DW, Frith AE, et al. Randomized phase Ⅲ trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC)[J]. J Clin Oncol, 2020, 38(15 suppl): 1016.
|
| [25] |
Park YH, Im SA, Kim SB, et al. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER-2-negative metastatic breast cancer[J]. Eur J Cancer, 2017, 86: 385-393.
|
| [26] |
Twelves C, Anthoney A, Savulsky CI, et al. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine[J]. Br J Cancer, 2019, 120(6): 579-586.
|
| [27] |
Jiang Z, Yang Y, Li L, et al. Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis[J]. J Cancer Res Ther, 2018, 14(Supplement): S957-S963.
|
| [28] |
Pivot X, Im SA, Guo M, et al. Subgroup analysis of patients with HER-2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine[J]. Breast Cancer, 2018, 25(3): 370-374.
|
| [29] |
Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial[J]. Lancet Oncol, 2017, 18(3): 371-383.
|
| [30] |
Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies[J]. N Engl J Med, 1987, 317(24): 1490-1495.
|
| [31] |
Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials[J]. J Clin Oncol, 2011, 29(16): 2144-2149.
|
| [32] |
Ciruelos E, Pérez-García JM, Gavilá J, et al. Maintenance therapy in HER-2-negative metastatic breast cancer: A new approach for an old concept[J]. Clin Drug Investig, 2019, 39(7): 595-606.
|
| [33] |
Rossi S, Schinzari G, Basso M, et al. Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review[J]. Future Oncol, 2016, 12(10): 1299-1307.
|
| [34] |
Ciruelos E, Pérez-García JM，Gavilá J, et al. Maintenance therapy in HER2-negative metastatic breast cancer: a new approach for an old concept [J]. Clin Drug Investig, 2019, 39(7): 595-606.
|
| [35] |
徐兵河，王树森，江泽飞，等. 中国晚期乳腺癌维持治疗专家共识[J/CD]. 中华普通外科学文献(电子版), 2018, 12(1): 1-5.
|
| [36] |
Cazzaniga ME, Dionisio MR，Riva F. Metronomic chemotherapy for advanced breast cancer patients[J]. Cancer Lett, 2017, 400: 252-258.
|
| [37] |
Fedele P, Marino A, Orlando L, et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer[J]. Eur J Cancer, 2012, 48(1): 24-29.
|
| [38] |
Krajnak S, Schnatz C, Almstedt K, et al. Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study[J]. Breast Cancer Res Treat, 2020, 182(2): 389-399.
|
| [39] |
Thomssen C, Lüftner D, Untch M, et al. International consensus conference for advanced breast cancer, Lisbon 2019: ABC5 consensus - assessment by a german group of experts[J]. Breast Care (Basel), 2020, 15(1): 82-95.
|
| [40] |
Harbeck N, Gnant M. Breast cancer[J]. Lancet, 2017, 389(10 074): 1134-1150.
|